JP2013519636A5 - - Google Patents

Download PDF

Info

Publication number
JP2013519636A5
JP2013519636A5 JP2012552352A JP2012552352A JP2013519636A5 JP 2013519636 A5 JP2013519636 A5 JP 2013519636A5 JP 2012552352 A JP2012552352 A JP 2012552352A JP 2012552352 A JP2012552352 A JP 2012552352A JP 2013519636 A5 JP2013519636 A5 JP 2013519636A5
Authority
JP
Japan
Prior art keywords
fviii
domain
linked
psa
fviii variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012552352A
Other languages
English (en)
Japanese (ja)
Other versions
JP5933457B2 (ja
JP2013519636A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/051723 external-priority patent/WO2011101267A1/en
Publication of JP2013519636A publication Critical patent/JP2013519636A/ja
Publication of JP2013519636A5 publication Critical patent/JP2013519636A5/ja
Application granted granted Critical
Publication of JP5933457B2 publication Critical patent/JP5933457B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012552352A 2010-02-16 2011-02-07 コンジュゲートｆｖｉｉｉバリアント Expired - Fee Related JP5933457B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10153718.1 2010-02-16
EP10153718 2010-02-16
US30560810P 2010-02-18 2010-02-18
US61/305,608 2010-02-18
PCT/EP2011/051723 WO2011101267A1 (en) 2010-02-16 2011-02-07 Conjugated fviii variants

Publications (3)

Publication Number Publication Date
JP2013519636A JP2013519636A (ja) 2013-05-30
JP2013519636A5 true JP2013519636A5 (enExample) 2014-03-27
JP5933457B2 JP5933457B2 (ja) 2016-06-08

Family

ID=42173354

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012553254A Expired - Fee Related JP5914363B2 (ja) 2010-02-16 2011-02-02 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子
JP2012552352A Expired - Fee Related JP5933457B2 (ja) 2010-02-16 2011-02-07 コンジュゲートｆｖｉｉｉバリアント

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2012553254A Expired - Fee Related JP5914363B2 (ja) 2010-02-16 2011-02-02 低減されたｖｗｆ結合を有する因子ｖｉｉｉ分子

Country Status (5)

Country Link
US (4) US20130040888A1 (enExample)
EP (2) EP2536753B1 (enExample)
JP (2) JP5914363B2 (enExample)
CN (3) CN105524164A (enExample)
WO (2) WO2011101242A1 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6263355A (ja) * 1985-09-13 1987-03-20 Hitachi Ltd バツテリバツクアツプｒａｍのチエツク方法
CA2670618C (en) 2006-12-15 2016-10-04 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
WO2010091122A1 (en) 2009-02-03 2010-08-12 Amunix, Inc. Extended recombinant polypeptides and compositions comprising same
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
PL2459224T3 (pl) 2009-07-27 2017-08-31 Baxalta GmbH Koniugaty białka związanego z krzepnięciem krwi
RU2533619C2 (ru) 2009-07-27 2014-11-20 Лайпоксен Текнолоджиз Лимитед Гликополисиалирование белков, не являющихся белками свертывания крови
NZ598056A (en) 2009-07-27 2014-01-31 Baxter Int Blood coagulation protein conjugates
EP2470559B1 (en) 2009-08-24 2017-03-22 Amunix Operating Inc. Coagulation factor ix compositions and methods of making and using same
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
JP6138052B2 (ja) 2010-12-22 2017-05-31 バクスアルタ ゲーエムベーハー 水溶性脂肪酸誘導体をタンパク質に抱合させるための材料および方法
RS59670B1 (sr) * 2012-01-12 2020-01-31 Bioverativ Therapeutics Inc Himerni polipeptidi faktora viii i njihove upotrebe
HUE043537T2 (hu) 2012-02-15 2019-08-28 Bioverativ Therapeutics Inc Rekombináns VIII faktor fehérjék
PT2814840T (pt) 2012-02-15 2020-01-28 Bioverativ Therapeutics Inc Composições de fator viii e métodos de produção e utilização das mesmas
MD20140123A2 (ro) * 2012-04-16 2015-04-30 Cantab Biopharmaceuticals Patents Limited Agenţi terapeutici optimizaţi pentru administrare subcutanată
RS59876B1 (sr) * 2012-07-11 2020-03-31 Bioverativ Therapeutics Inc Kompleks faktora viii sa xten i proteinom fon vilebrandovog faktora, i njihova primena
JP2015533152A (ja) 2012-10-15 2015-11-19 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 第ｖｉｉ因子コンジュゲート
DK2796145T3 (da) * 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
TW202003554A (zh) * 2013-08-14 2020-01-16 美商百歐維拉提夫治療公司 因子ｖｉｉｉ－ｘｔｅｎ融合物及其用途
ES2819217T3 (es) * 2013-09-08 2021-04-15 Kodiak Sciences Inc Conjugados de polímeros iónicos dipolares y factor VIII
BR112016008039A2 (pt) 2013-10-15 2017-10-17 Novo Nordisk Healthcare Ag polipeptídeos do fator vii da coagulação
EP3091997B1 (en) 2014-01-10 2022-07-06 Bioverativ Therapeutics Inc. Factor viii chimeric proteins and uses thereof
AR101060A1 (es) * 2014-02-12 2016-11-23 Novo Nordisk As Conjugados de fviii
AR099328A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados de factor vii
AR099340A1 (es) * 2014-02-12 2016-07-13 Novo Nordisk As Conjugados del factor de coagulación ix
CN106459180A (zh) * 2014-03-23 2017-02-22 爱德技术生物科学有限公司 在铜使用下重组蛋白表达的增强
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
WO2016020210A1 (en) 2014-08-04 2016-02-11 Csl Behring Gmbh Csl behring gmbh
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
EP3042952A1 (en) * 2015-01-07 2016-07-13 CEVEC Pharmaceuticals GmbH O-glycan sialylated recombinant glycoproteins and cell lines for producing the same
CN107406493B (zh) 2015-03-06 2021-08-13 康诺贝林伦瑙有限公司 具有改善的半衰期的经修饰的血管性血友病因子
JP6909203B2 (ja) 2015-08-03 2021-07-28 バイオベラティブ セラピューティクス インコーポレイテッド 第ｉｘ因子融合タンパク質及びそれらの製造方法及び使用方法
WO2017117464A1 (en) * 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
CN109790529A (zh) 2016-06-24 2019-05-21 财团法人牧岩生命科学研究所 包含FVIII和vWF因子的嵌合蛋白及其用途
CN109689683A (zh) * 2016-06-24 2019-04-26 财团法人牧岩生命科学研究所 重组单链fvⅲ及其化学缀合物
BR112019011115A2 (pt) 2016-12-02 2019-10-01 Bioverativ Therapeutics Inc. métodos para tratar artropatia hemofílica usando fatores de coagulação quiméricos
EP3382014A1 (en) 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
CN111183151B (zh) 2017-06-23 2024-06-07 武田药品工业株式会社 因子viii亚种的纯化
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
BR112020017872A2 (pt) 2018-03-02 2020-12-22 Kodiak Sciences Inc. Anticorpos de il-6 e construtos de fusão e conjugados dos mesmos
BR112020022164A2 (pt) 2018-05-18 2021-02-02 Bioverativ Therapeutics Inc. métodos de tratamento de hemofilia a
EP3816181A4 (en) 2018-05-18 2022-04-20 Zhengzhou Gensciences Inc. Improved fviii fusion protein and use thereof
KR20220029733A (ko) 2019-07-04 2022-03-08 체에스엘 베링 렝나우 아게 응고 인자 viii의 시험관내 안정성을 증가시키기 위한 절단된 폰 빌레브란트 인자 (vwf)
EP4021479A2 (en) 2019-08-27 2022-07-06 Tonix Pharma Limited Modified tff2 polypeptides
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP7680442B2 (ja) 2019-11-11 2025-05-20 ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト 第ｖｉｉｉ因子に対する寛容を誘導するためのポリペプチド

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
AU2645588A (en) 1987-12-04 1989-06-15 Scripps Clinic And Research Foundation The von willebrand factor binding domain of factor viii
US5629384A (en) 1994-05-17 1997-05-13 Consiglio Nazionale Delle Ricerche Polymers of N-acryloylmorpholine activated at one end and conjugates with bioactive materials and surfaces
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
DE4437544A1 (de) * 1994-10-20 1996-04-25 Behringwerke Ag Einsatz von vWF-enthaltenden Konzentraten als Kombinationstherapie bei Therapie mit Antithrombotika und Fibrinolytika
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO1999055377A2 (en) 1998-04-28 1999-11-04 Applied Research Systems Ars Holding N.V. Polyol-ifn-beta conjugates
US6759216B1 (en) * 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
BRPI0213207B1 (pt) 2001-10-10 2021-06-15 Novo Nordisk A/S Processo in vitro, isento de células, para a remodelagem de um peptídeo e processos para formar um conjugado entre peptídeos e um grupo de modificação
US7157277B2 (en) * 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
CA2466027C (en) * 2001-11-07 2013-01-08 Nektar Therapeutics Al, Corporation Branched polymers and their conjugates
DE60315949T2 (de) 2002-01-16 2008-06-12 Biocompatibles Uk Ltd., Farnham Polymerkonjugate
EP1654290B1 (en) 2003-08-12 2019-03-13 Lipoxen Technologies Limited Sialic acid derivatives for protein derivatisation and conjugation
LT2371856T (lt) 2004-11-12 2022-08-25 Bayer Healthcare Llc Fviii modifikacija, nukreipta į tam tikrą vietą
WO2006090119A1 (en) 2005-02-23 2006-08-31 Lipoxen Technologies Limited Activated sialic acid derivatives for protein derivatisation and conjugation
EP1863921B1 (en) 2005-03-24 2011-10-05 BioGeneriX AG Expression of soluble, active eukaryotic glycosyltransferases in prokaryotic organisms
EP1871801A2 (en) * 2005-04-01 2008-01-02 Novo Nordisk Health Care AG Blood coagulation fviii analogues
EP1893239A2 (en) 2005-06-15 2008-03-05 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of growth hormone
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
EP1981977B1 (en) 2006-01-31 2015-12-23 National Research Council Of Canada Production of polysialic acid containing glyconjugates using a self-priming polysialyltransferase
CA2647314A1 (en) 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
WO2008011633A2 (en) * 2006-07-21 2008-01-24 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
CA2670618C (en) 2006-12-15 2016-10-04 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
CN101778937A (zh) * 2007-06-04 2010-07-14 诺和诺德公司 使用n-乙酰葡糖胺转移酶的o-联糖基化
WO2008151448A1 (en) 2007-06-15 2008-12-18 National Research Council Of Canada Engineered versions of polysialyltransferases with enhanced enzymatic properties
WO2009062100A1 (en) 2007-11-09 2009-05-14 Baxter International Inc. Modified recombinant factor viii and von willebrand factor and methods of use
CN102037004A (zh) 2008-01-08 2011-04-27 生物种属学股份公司 使用寡糖基转移酶的多肽的糖缀合
CN101965200B (zh) * 2008-02-27 2013-06-19 诺沃-诺迪斯克有限公司 缀合的因子ⅷ分子
PL2291523T3 (pl) 2008-06-24 2015-05-29 Csl Behring Gmbh Czynnik VIII, czynnik von Willebranda lub ich kompleksy o wydłużonym okresie półtrwania in vivo
KR101929641B1 (ko) 2008-10-17 2018-12-14 박스알타 인코퍼레이티드 낮은 수준의 수용성 중합체를 포함하는 개질된 혈액 인자
CN102333788A (zh) 2009-02-19 2012-01-25 诺沃—诺迪斯克有限公司 因子viii的修饰
ES2427627T3 (es) * 2009-04-06 2013-10-31 Novo Nordisk A/S Entrega dirigida de proteínas de Factor VIII a plaquetas
US9493543B2 (en) * 2010-02-16 2016-11-15 Novo Nordisk A/S Factor VIII fusion protein

Similar Documents

Publication Publication Date Title
JP2013519636A5 (enExample)
JP2013519697A5 (enExample)
JP2010215657A5 (enExample)
IN2014DN00101A (enExample)
EA201890389A2 (ru) Композиции конъюгата xten и способы их получения
JP2012255007A5 (enExample)
JP2011515499A5 (enExample)
JP2015536943A5 (enExample)
CR20110515A (es) Compuesto biocompatible y su uso
JP2015519313A5 (enExample)
JP2012508172A5 (enExample)
EA201170039A1 (ru) Полимерные частицы, нагруженные лекарственным средством, и способы их получения и применения
JP2014515039A5 (enExample)
BR112012012210B8 (pt) conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano
WO2010122385A8 (fr) Formulation a action rapide d'insuline
HK1205156A1 (en) Cyclodextrin-based polymers for therapeutic delivery
SG194175A1 (en) Polymer conjugated prostaglandin analogues
IN2012DN00407A (enExample)
UA101497C2 (ru) Конъюгаты фактора ix с увеличенным временем полужизни
WO2012017288A3 (en) Supramolecular complexes of polyanionic polymers and spermidine in tissue maintenance and repair
MX2022003939A (es) Composicion farmaceutica de estabilidad mejorada.
CA2402421A1 (en) Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals
WO2018056937A3 (en) Nanofibrous adhesion barrier
JP2016529286A5 (enExample)
WO2007097888A3 (en) Fluoroquinolone carboxylic acid salt compositions